Identification of human immunodeficiency virus-1 specific CD8 + and CD4 + T cell responses in perinatally-infected infants and their mothers

AIDS

Volumn 23, Issue 7, 2009, Pages 789-798

  Shalekoff, Sharon ^a,b   Meddows Taylor, Stephen ^a,b   Gray, Glenda E ^c   Sherman, Gayle G ^b,d   Coovadia, Ashraf H ^e   Kuhn, Louise ^f   Tiemessen, Caroline T ^a,b  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f Columbia University ^*  (United States)

Author keywords

CD4 +T cell responses; CD8 + T cell responses; Hiv infected infants and mothers; Hiv specific T cell responses

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; LAMIVUDINE; NEF PROTEIN; NEVIRAPINE; POL PROTEIN; STAVUDINE; VIRUS ENVELOPE PROTEIN; CYTOKINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MATERNAL DISEASE; NONHUMAN; PERINATAL INFECTION; PRENATAL PERIOD; PRIORITY JOURNAL; SINGLE DRUG DOSE; TARGET CELL; VERTICAL TRANSMISSION; VIRUS LOAD; CLINICAL TRIAL; DISEASE TRANSMISSION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; MULTICENTER STUDY; PREGNANCY; PREGNANCY COMPLICATION; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 67649644707     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328329c784     Document Type: Article

References (40)

1. Taha TE, Graham SM, Kumwenda NI, et al. Morbidity among human immunodeficiency virus-1-infected and -uninfected African children. Pediatrics 2000;106:E77.
2. Barnhart HX, Caldwell MB, Thomas P, et al. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics 1996;97:710-716.
3. Natural history of vertically acquired human immunodeficiency virus-1 infection. The European Collaborative Study. Pediatrics 1994;94:815-819.
4. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including theCASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000;355:1131-1137.
5. Goulder PJ, Pasquier C, Holmes EC, et al. Mother-to-child transmission of HIV infection and CTL escape through HLA- A2-SLYNTVATL epitope sequence variation. Immunol Lett 2001; 79:109-116.
6. Scarlatti G, Leitner T, Halapi E, et al. Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNAand DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci USA1993; 90:1721-1725.
7. Goulder PJ, Brander C, Tang Y, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412:334-338.
8. Kuhn L, Abrams EJ, Palumbo P, et al. Maternal versus paternal inheritance of HLA class I alleles among HIV-infected children: consequences for clinical disease progression. AIDS 2004; 18:1281-1289.
9. Luzuriaga K, Koup RA, Pikora CA, Brettler DB, Sullivan JL. Deficient human immunodeficiency virus type 1-specific cy- totoxic T cell responses in vertically infected children. J Pediatr 1991;119:230-236.
10. Luzuriaga K, McQuilken P, Alimenti A, Somasundaran M, Hesselton R, Sullivan JL. Early viremia and immune responses in vertical human immunodeficiency virus type 1 infection. J Infect Dis 1993;167:1008-1013.
11. Scott ZA, Chadwick EG, Gibson LL, et al. Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8+ T cell responses in young HIV-1-infected infants. J Immunol 2001;167:7134-7140.
12. Luzuriaga K, Holmes D, Hereema A, Wong J, Panicali DL, Sullivan JL. HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J Immunol 1995;154:433-443.
13. Spiegel HM, Chandwani R, Sheehy ME, et al. The impact of early initiation of highly active antiretroviral therapy on the human immunodeficiency virus type 1-specific CD8 T cell response in children. J Infect Dis 2000;182:88-95.
14. Buseyne F, Burgard M, Teglas JP, et al. Early HIV-specific cytotoxic T lymphocytes and disease progression in children born to HIV-infected mothers. AIDS Res Hum Retroviruses 1998;14:1435-1444.
15. ThobakgaleCF, Ramduth D, ReddyS, etal. HIV-specific CD8R Tcell activity is detectable from birth in the majority of in utero infected infants. J Virol 2007;81:12775-12784.
16. Ramduth D, ThobakgaleCF, Mkhwanazi NP, etal. Detection of HIV type 1 gag-specific CD4+ T cell responses in acutely infected infants. AIDS Res Hum Retroviruses 2008; 24:265-270.
17. De Rosa SC, Lu FX, Yu J, etal. Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004;173:5372-5380.
18. Kuhn L, Schramm DB, DonningerS, etal. African infants'CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine. AIDS 2007;21:1753-1761.
19. Williamson C, Morris L, Maughan MF, etal. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses 2003;19:133-144.
20. Bansal A, Gough E, Sabbaj S, etal. CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides. AIDS 2005;19:241-250.
21. Betts MR, Ambrozak DR, Douek DC, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001;75:11983-11991.
22. Sester M, Sester U, Kohler H, et al. Rapid whole blood analysis of virus-specific CD4 and CD8 T cell responses in persistent HIV infection. AIDS 2000;14:2653-2660.
23. Ramduth D, Chetty P, Mngquandaniso NC, et al. Differential immunogenicity of HIV-1 clade C proteins in eliciting CD8R and CD4R cell responses. J Infect Dis 2005;192:1588-1596.
24. Draenert R, Altfeld M, Brander C, et al. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods 2003; 275:19-29.
25. Kaushik S, Vajpayee M, Wig N, Seth P. Characterization of HIV-1 Gag-specific T cell responses in chronically infected Indian population. Clin Exp Immunol 2005;142:388-397.
26. Shalekoff S, Meddows-Taylor S, Schramm DB, et al. Host CCL3L1 gene copy number in relation to HIV-1-specific CD4R and CD8R T-cell responses and viral load in South African women. J Acquir Immune Defic Syndr 2008;48:245-254.
27. Buseyne F, Scott-Algara D, Corre B, et al. Poor recognition of HIV-1 Nef protein by CD8 T cells from HIV-1-infected children: impact of age. Virology 2006; 354:271-279.
28. Yang OO, Sarkis PT, Ali A, et al. Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med 2003;197:1365-1375.
29. Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991; 350:508-511.
30. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996; 2:338-342.
31. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D.HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;391:397-401.
32. Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 2001;410:834-838.
33. Lichterfeld M, Yu XG, Cohen D, et al. HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS 2004; 18:1383-1392.
34. Addo MM, Altfeld M, Rosenberg ES, etal. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 2001;98:1781-1786.
35. Cao J, McNevin J, Holte S, Fink L, Corey L, McElrath MJ. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8R T cells in primary HIV-1 infection. JVirol 2003;77:6867-6878.
36. Alter G, Merchant A, Tsoukas CM, et al. Human immunodeficiency virus (HIV)-specific effector CD8T cell activity inpatients with primary HIV infection. J Infect Dis 2002; 185:755-765.
37. Dalod M, Dupuis M, Deschemin JC, et al. Weak anti-HIV CD8+ T-cell effector activity in HIV primary infection. J Clin Invest 1999;104:1431-1439.
38. Lohman BL, Slyker JA, Richardson BA, et al. Longitudinal assessment of human immunodeficiency virus type 1 (HIV- 1)-specific gamma interferon responses during the first year of life in HIV-1-infected infants. J Virol 2005;79:8121-8130.
39. Sanchez-Merino V, Farrow MA, Brewster F, Somasundaran M, Luzuriaga K. Identification and characterization of HIV-1 CD8R T cell escape variants with impaired fitness. J Infect Dis 2008; 197:300-308.
40. Sanchez-Merino V, Nie S, Luzuriaga K. HIV-1-specific CD8R T cell responses and viral evolution in women and infants. J Immunol 2005;175:6976-6986.